Today, we have initiated a joint research project on cancer immunotherapy between the National Cancer Center Japan and Dojin Institute of Cancer Immunology. By combining the know-how related to cancer immunotherapy possessed by the National Cancer Research Center Japan and the knowledge that we have accumulated in clinical practice of cancer immunotherapy, we will conduct research and development for the more effective cancer immunotherapy.

Outline of joint research

Joint research theme: Research and development of Hexa-Complex Immunotherapy with anti-PD-1 antibody

Joint research period: From July 1st, 2023 to June 30th, 2025